[go: up one dir, main page]

WO2017037594A3 - 用于减少局部脂肪的医药组成物及其用途 - Google Patents

用于减少局部脂肪的医药组成物及其用途 Download PDF

Info

Publication number
WO2017037594A3
WO2017037594A3 PCT/IB2016/055102 IB2016055102W WO2017037594A3 WO 2017037594 A3 WO2017037594 A3 WO 2017037594A3 IB 2016055102 W IB2016055102 W IB 2016055102W WO 2017037594 A3 WO2017037594 A3 WO 2017037594A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
fat
composition used
reducing localised
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2016/055102
Other languages
English (en)
French (fr)
Other versions
WO2017037594A2 (zh
Inventor
凌玉芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caliway Biopharmaceuticals Co Ltd
Caliway (usa) Co Ltd
Original Assignee
Caliway Biopharmaceuticals Co Ltd
Caliway (usa) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58186932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017037594(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2015/088340 external-priority patent/WO2016029870A1/zh
Priority to PL16840922.5T priority Critical patent/PL3381451T3/pl
Priority to SG11201801111RA priority patent/SG11201801111RA/en
Priority to KR1020187008138A priority patent/KR102107917B1/ko
Priority to CN202211455288.2A priority patent/CN115778928B/zh
Priority to EP16840922.5A priority patent/EP3381451B1/en
Priority to JP2018510970A priority patent/JP7063803B2/ja
Priority to HRP20251142TT priority patent/HRP20251142T1/hr
Priority to EP25196769.1A priority patent/EP4647070A2/en
Priority to FIEP16840922.5T priority patent/FI3381451T3/fi
Priority to US15/754,429 priority patent/US10610496B2/en
Priority to ES16840922T priority patent/ES3041835T3/es
Priority to IL257784A priority patent/IL257784B2/en
Priority to CA2995158A priority patent/CA2995158C/en
Priority to AU2016314546A priority patent/AU2016314546C1/en
Priority to CN201680046418.3A priority patent/CN108697668B/zh
Priority to BR112018003877-6A priority patent/BR112018003877A2/pt
Priority to DK16840922.5T priority patent/DK3381451T3/da
Priority to MX2018002462A priority patent/MX384073B/es
Application filed by Caliway Biopharmaceuticals Co Ltd, Caliway (usa) Co Ltd filed Critical Caliway Biopharmaceuticals Co Ltd
Priority to SM20250365T priority patent/SMT202500365T1/it
Priority to KR1020207012125A priority patent/KR102356390B1/ko
Priority to LTEPPCT/IB2016/055102T priority patent/LT3381451T/lt
Publication of WO2017037594A2 publication Critical patent/WO2017037594A2/zh
Priority to TW106128816A priority patent/TWI667044B/zh
Priority to CA3033041A priority patent/CA3033041A1/en
Priority to JP2019510854A priority patent/JP2019528297A/ja
Priority to KR1020197008320A priority patent/KR20190040305A/ko
Priority to CN201780050055.5A priority patent/CN109640969A/zh
Priority to PCT/IB2017/055129 priority patent/WO2018037384A1/zh
Priority to EP17843043.5A priority patent/EP3505168A1/en
Priority to RU2019108198A priority patent/RU2753507C2/ru
Priority to US16/327,466 priority patent/US10716824B2/en
Anticipated expiration legal-status Critical
Priority to CONC2018/0003424A priority patent/CO2018003424A2/es
Publication of WO2017037594A3 publication Critical patent/WO2017037594A3/zh
Priority to AU2019280037A priority patent/AU2019280037B2/en
Priority to US16/749,266 priority patent/US11433034B2/en
Priority to US16/749,347 priority patent/US11318110B2/en
Priority to US16/926,631 priority patent/US20200338152A1/en
Priority to US17/875,679 priority patent/US12357588B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供一种用于减少局部脂肪的医药组成物，包含表面活性剂所形成的多个含药微胞、以及被包覆在所述含药微胞中的姜黄素。所述用于减少局部脂肪的医药组成物可减少施用部位的脂肪，且具有高稳定性、高度脂肪组织生体可用率、低副作用、以及缓释等优点。
PCT/IB2016/055102 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途 Ceased WO2017037594A2 (zh)

Priority Applications (36)

Application Number Priority Date Filing Date Title
LTEPPCT/IB2016/055102T LT3381451T (lt) 2015-08-28 2016-08-26 Farmacinis junginys, naudojamas lokalizuotiems riebalams mažinti, ir farmacinio junginio naudojimas
IL257784A IL257784B2 (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
KR1020207012125A KR102356390B1 (ko) 2015-08-28 2016-08-26 국부 지방을 감소시키기 위해 사용되는 제약 조성물 및 그의 용도
KR1020187008138A KR102107917B1 (ko) 2015-08-28 2016-08-26 국부 지방을 감소시키기 위해 사용되는 제약 조성물 및 그의 용도
CN202211455288.2A CN115778928B (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途
EP16840922.5A EP3381451B1 (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
JP2018510970A JP7063803B2 (ja) 2015-08-28 2016-08-26 局所脂肪の減少に用いる医薬組成物およびその用途
HRP20251142TT HRP20251142T1 (hr) 2015-08-28 2016-08-26 Farmaceutski pripravak koji se koristi za smanjenje lokaliziranih masnoća i uporaba farmaceutskog pripravka
EP25196769.1A EP4647070A2 (en) 2015-08-28 2016-08-26 A pharmaceutical composition for reducing local fat and uses thereof
FIEP16840922.5T FI3381451T3 (fi) 2015-08-28 2016-08-26 Lääkekoostumus käytettäväksi paikallisen rasvan vähentämisessä ja lääkekoostumuksen käyttö
US15/754,429 US10610496B2 (en) 2015-08-28 2016-08-26 Pharmaceutical composition for reducing local fat and uses thereof
ES16840922T ES3041835T3 (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
SG11201801111RA SG11201801111RA (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
CA2995158A CA2995158C (en) 2015-08-28 2016-08-26 A pharmaceutical composition for reducing local fat and uses thereof
AU2016314546A AU2016314546C1 (en) 2015-08-28 2016-08-26 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
CN201680046418.3A CN108697668B (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途
BR112018003877-6A BR112018003877A2 (pt) 2015-08-28 2016-08-26 “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
DK16840922.5T DK3381451T3 (da) 2015-08-28 2016-08-26 Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
MX2018002462A MX384073B (es) 2015-08-28 2016-08-26 Una composicion farmaceutica para reducir la grasa localizada y sus usos.
PL16840922.5T PL3381451T3 (pl) 2015-08-28 2016-08-26 Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
SM20250365T SMT202500365T1 (it) 2015-08-28 2016-08-26 Composizione farmaceutica utilizzata per ridurre il grasso localizzato e uso della composizione farmaceutica
TW106128816A TWI667044B (zh) 2015-11-20 2017-08-24 用於減少體重的皮下注射劑及其用途
CA3033041A CA3033041A1 (en) 2016-08-26 2017-08-25 A subcutaneous injection formulation for reducing body weight and uses thereof
RU2019108198A RU2753507C2 (ru) 2015-11-20 2017-08-25 Композиция подкожной инъекции для снижения массы тела и ее применения
US16/327,466 US10716824B2 (en) 2016-08-26 2017-08-25 Subcutaneous injection formulation for reducing body weight and uses thereof
JP2019510854A JP2019528297A (ja) 2015-11-20 2017-08-25 体重減少に用いられる皮下注射製剤およびその用途
EP17843043.5A EP3505168A1 (en) 2016-08-26 2017-08-25 Subcutaneous injection for reducing body weight and application thereof
KR1020197008320A KR20190040305A (ko) 2016-08-26 2017-08-25 체중 감소를 위한 피하 주사제 및 그의 용도
CN201780050055.5A CN109640969A (zh) 2016-08-26 2017-08-25 用于減少体重的皮下注射剂及其用途
PCT/IB2017/055129 WO2018037384A1 (zh) 2016-08-26 2017-08-25 用于減少体重的皮下注射剂及其用途
CONC2018/0003424A CO2018003424A2 (es) 2015-08-28 2018-03-27 Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
AU2019280037A AU2019280037B2 (en) 2015-08-28 2019-12-12 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
US16/749,347 US11318110B2 (en) 2015-08-28 2020-01-22 Pharmaceutical composition for reducing local fat and uses thereof
US16/749,266 US11433034B2 (en) 2015-08-28 2020-01-22 Pharmaceutical composition for reducing local fat and uses thereof
US16/926,631 US20200338152A1 (en) 2016-08-26 2020-07-10 Subcutaneous injection formulation for reducing body weight and uses thereof
US17/875,679 US12357588B2 (en) 2015-08-28 2022-07-28 Pharmaceutical composition for reducing local fat and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/088340 2015-08-28
PCT/CN2015/088340 WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用
US201562257846P 2015-11-20 2015-11-20
US62/257,846 2015-11-20
US201662299702P 2016-02-25 2016-02-25
US62/299,702 2016-02-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/088340 Continuation WO2016029870A1 (zh) 2014-08-28 2015-08-28 用于减少局部脂肪与减少体重的组合物及其医药品与应用

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/754,429 A-371-Of-International US10610496B2 (en) 2015-08-28 2016-08-26 Pharmaceutical composition for reducing local fat and uses thereof
US16/749,266 Division US11433034B2 (en) 2015-08-28 2020-01-22 Pharmaceutical composition for reducing local fat and uses thereof
US16/749,347 Continuation-In-Part US11318110B2 (en) 2015-08-28 2020-01-22 Pharmaceutical composition for reducing local fat and uses thereof

Publications (2)

Publication Number Publication Date
WO2017037594A2 WO2017037594A2 (zh) 2017-03-09
WO2017037594A3 true WO2017037594A3 (zh) 2018-08-23

Family

ID=58186932

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2016/055101 Ceased WO2017037593A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途
PCT/IB2016/055102 Ceased WO2017037594A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/055101 Ceased WO2017037593A2 (zh) 2015-08-28 2016-08-26 用于减少局部脂肪的医药组成物及其用途

Country Status (23)

Country Link
US (4) US20180243211A1 (zh)
EP (3) EP3381451B1 (zh)
JP (5) JP7063804B2 (zh)
KR (4) KR102240221B1 (zh)
CN (4) CN115778928B (zh)
AU (5) AU2016314545C1 (zh)
BR (2) BR112018003892A2 (zh)
CA (2) CA2995155C (zh)
CO (1) CO2018003424A2 (zh)
DK (1) DK3381451T3 (zh)
ES (1) ES3041835T3 (zh)
FI (1) FI3381451T3 (zh)
HR (1) HRP20251142T1 (zh)
IL (1) IL257784B2 (zh)
LT (1) LT3381451T (zh)
MX (3) MX384073B (zh)
PL (1) PL3381451T3 (zh)
PT (1) PT3381451T (zh)
RU (1) RU2753507C2 (zh)
SG (1) SG11201801111RA (zh)
SM (1) SMT202500365T1 (zh)
TW (3) TWI604859B (zh)
WO (2) WO2017037593A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537548B2 (en) 2014-08-28 2020-01-21 Caliway Biopharmaceuticals Co., Ltd. Composition and medical product for reducing body weight and body fat, and use of said product
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
EP3381451B1 (en) * 2015-08-28 2025-08-20 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
EP3505168A1 (en) 2016-08-26 2019-07-03 Caliway Biopharmaceuticals Co., Ltd. Subcutaneous injection for reducing body weight and application thereof
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
CN110446492A (zh) * 2017-03-28 2019-11-12 康霈生技股份有限公司 用于减少体重及减少体脂肪的组合物及其医药品与应用
JP2022520778A (ja) * 2019-02-11 2022-04-01 ハルステッド，ヨセフ 治療目的で投与可能な高用量非水クルクミノイド溶液
EP3946407A4 (en) * 2019-03-24 2022-12-28 Patel, Naishadhkumar Ramubhai Formulation to enhance the bioavailibity and stability of curcuminoids and/or its derivatives thereof
CN110934827B (zh) * 2019-11-08 2021-03-19 江西中医药大学 一种口服葛根素混合胶束制剂、制备方法及应用
CN113730650B (zh) * 2021-10-13 2022-11-01 哈尔滨泽润医疗机构管理有限公司 一种碳水溶酶组合物及其制备方法和应用
KR102691705B1 (ko) * 2021-10-25 2024-08-06 주식회사 지엘케이인터내셔날 지방 분해용 조성물
CN119255715A (zh) * 2022-03-28 2025-01-03 路易斯安娜州立大学监测委员会，农业和机械学院 用于提高胰岛素敏感性的协同作用
US12111372B2 (en) 2022-04-25 2024-10-08 GE Precision Healthcare LLC Wireless coil adaptor for a magnetic resonance imaging system
US20230372378A1 (en) * 2022-05-16 2023-11-23 Caliway Biopharmaceuticals Co., Ltd. Compositions and methods for alleviating conditions caused by abnormal subcutaneous deposit of adipose tissue or fat
IL320641A (en) * 2022-11-22 2025-07-01 Caliway Biopharmaceuticals Co Ltd Method for treating and/or preventing cellulite

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021703A1 (en) * 1998-12-30 2001-09-13 Kosak Kenneth M. Biocleavable micelle compositions for use as drug carriers
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
US20110151103A1 (en) * 2004-04-19 2011-06-23 Makarand Gore System and a Method for Pharmaceutical Dosage Preparation Using Jettable Microemulsions
WO2014138426A2 (en) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2017037593A2 (zh) * 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60019902D1 (de) * 1999-03-03 2005-06-09 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
DE60031921T2 (de) * 1999-08-16 2007-09-20 Dsm Ip Assets B.V. Verfahren zu Herstellung von Epigallocatechin Gallate
US6475530B1 (en) 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US20040071799A1 (en) 2001-02-12 2004-04-15 Xiurong Xu Herbal compositions and methods for effecting weight loss in humans
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
ES2329370T3 (es) * 2003-06-04 2009-11-25 Nestec S.A. Bebida para el control del peso.
CN100539988C (zh) * 2003-06-27 2009-09-16 株式会社太平洋 含有生理活性成分的自聚集聚合物纳米颗粒和含有该纳米颗粒的外用搽剂
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
WO2006074278A2 (en) 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
AU2006210114B2 (en) * 2005-02-04 2011-11-17 Peter Heger Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
ITFI20050031A1 (it) 2005-02-21 2006-08-22 Stefan Coccoloni Una composizione farmaceutica atta a prevenire l'invecchiamento e l'insorgere di malattie vascolari,neoplastiche,cutanee e dell'apparato pilifero
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
JP2007063137A (ja) * 2005-08-29 2007-03-15 Daicho Kikaku:Kk 抗肥満薬
WO2007041276A2 (en) 2005-09-29 2007-04-12 New Chapter, Inc. Methods for modulating apoptosis, cellgrowth, and protein expression with herbal compositions
JP2007131603A (ja) 2005-11-14 2007-05-31 Kaneka Corp Ｌ−カルニチン合成系酵素遺伝子の転写促進用組成物
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
EP1993365B1 (en) * 2006-03-06 2013-05-08 The Regents of the University of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20100015262A1 (en) 2006-03-31 2010-01-21 Regina Goralczyk Novel use of compounds and combinations of compounds for improving the physical appearance
US7977319B1 (en) 2006-04-03 2011-07-12 Scott David Levine Ultra-high fiber supplement and method of reducing weight, cardiovascular risks and ingested toxins
WO2007113008A2 (en) * 2006-04-04 2007-10-11 Dsm Ip Assets B.V. Opaque container comprising food or pharmaceutical products or herbal(s)
CN101095665A (zh) * 2006-06-27 2008-01-02 中国科学院上海生命科学研究院 Sirt1在预防、控制或治疗肥胖中的用途
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
CN101310718A (zh) * 2007-05-23 2008-11-26 中国科学院上海生命科学研究院 减肥降血脂的含儿茶素的组合物及其用途
CN102357226B (zh) 2007-08-07 2013-07-10 北京北大维信生物科技有限公司 中草药姜黄的醇提取物在制备具有脂肪酶活性抑制作用的药物中的应用
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
US20110009496A1 (en) * 2008-01-08 2011-01-13 Sirtris Pharmaceuticas, Inc. Resveratrol formulations
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
CA2726996C (en) * 2008-06-25 2017-08-29 Elc Management Llc Method and compositions for improving skin and body appearance
US20100215782A1 (en) 2008-10-22 2010-08-26 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
US8496974B2 (en) * 2008-11-25 2013-07-30 Oy Granula Ab Ltd Method for preparing a composition comprising a compound mixture and a carrier agent
AU2009319870A1 (en) * 2008-11-26 2011-07-14 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
EP2408442B1 (en) * 2009-03-20 2016-08-17 Bioxtract S.A. Pharmaceutical composition presenting anti-inflammatory properties
CN101874763A (zh) * 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물
CN101632655B (zh) 2009-08-04 2011-12-07 南京大渊美容保健有限公司 延缓衰老的白藜芦醇和生物类黄酮营养组合物
JP5594819B2 (ja) 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
KR101579079B1 (ko) * 2010-03-10 2015-12-21 애브비 바하마스 리미티드 고체 조성물
US8835509B2 (en) * 2010-05-31 2014-09-16 Arbro Pharmaceuticals Ltd. Self emulsifying drug delivery system for a curcuminoid based composition
AU2011271466B2 (en) 2010-07-02 2013-08-22 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
US20130245118A1 (en) * 2010-07-02 2013-09-19 Eric H. Kuhrts Stable fatty acid-containing formulations
KR101640258B1 (ko) * 2010-07-05 2016-07-15 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
US20130143869A1 (en) 2010-07-16 2013-06-06 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US20120088829A1 (en) * 2010-09-29 2012-04-12 MyCell Holdings Limited Formulations of Ubiquinol and Resveratrol Esters
CN102106816A (zh) * 2010-12-16 2011-06-29 天津迈迪瑞康生物医药科技有限公司 一种白藜芦醇纳米制剂及其制备方法
US8815310B2 (en) 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
CN102512404B (zh) 2011-11-18 2014-05-07 上海交通大学 一种姜黄素类化合物肺靶向制剂及其制备方法与应用
US9745279B2 (en) 2011-12-27 2017-08-29 Tokiwa Phytochemical Co., Ltd. Sirtuin activator
EP2804587B1 (en) * 2012-01-19 2019-05-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
US8496979B1 (en) 2012-02-02 2013-07-30 Reliv International, Inc. Caffeine-free dietary supplements for increasing energy and methods of administering the same
JP2015511585A (ja) 2012-02-29 2015-04-20 エイボン プロダクツ インコーポレーテッド Ｃｐｔ−１調節剤の使用及びその組成物
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
US9731015B2 (en) 2012-08-04 2017-08-15 Eric Hauser Kuhrts Water-soluble lipophilic natural compound formulations
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics
US9211298B2 (en) 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
DE202012012130U1 (de) * 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
CN103285401A (zh) * 2013-05-27 2013-09-11 沈阳药科大学 一种能提高难溶性药物溶解性和生物利用度的组合物
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
US10226413B2 (en) 2013-11-15 2019-03-12 Damy Chemical Co., Ltd. Solution solubilization composition of insoluble material and method for solubilizing insoluble material using same
US20160287533A1 (en) * 2013-11-27 2016-10-06 Research Foundation Of The City University Of New York Activity Enhancing Curcumin Compositions and Methods of Use
TW201540294A (zh) * 2014-04-25 2015-11-01 Caliway Biomedical Co Ltd 用於抑制脂肪細胞、降低體脂肪、減少體重或促進脂肪代謝之植物萃取組成物及其醫藥組合物與用途
CN103989659B (zh) * 2014-05-26 2016-09-07 重庆医科大学 姜黄素纳米结构脂质载体及其制备方法
KR101859345B1 (ko) * 2014-08-28 2018-05-18 칼리웨이 바이오파마슈티칼스 코., 엘티디. 국소 지방 및 체중 감소용 조성물 및 그의 제약 및 용도
US10226503B2 (en) 2014-08-28 2019-03-12 Caliway Biopharmaceuticals Co., Ltd. Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
KR101923840B1 (ko) 2014-08-28 2019-02-27 칼리웨이 바이오파마슈티칼스 코., 엘티디. 체중 및 체지방 감소용 조성물 및 의약 생성물, 및 상기 생성물의 용도
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
EP3505168A1 (en) 2016-08-26 2019-07-03 Caliway Biopharmaceuticals Co., Ltd. Subcutaneous injection for reducing body weight and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021703A1 (en) * 1998-12-30 2001-09-13 Kosak Kenneth M. Biocleavable micelle compositions for use as drug carriers
US20110151103A1 (en) * 2004-04-19 2011-06-23 Makarand Gore System and a Method for Pharmaceutical Dosage Preparation Using Jettable Microemulsions
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2014138426A2 (en) * 2013-03-07 2014-09-12 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2017037593A2 (zh) * 2015-08-28 2017-03-09 康霈生技股份有限公司 用于减少局部脂肪的医药组成物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANG ET AL.: "Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 17, no. 19, October 2013 (2013-10-01), pages 2578 - 2586, XP055536312 *

Also Published As

Publication number Publication date
AU2021202349A1 (en) 2021-05-13
HRP20251142T1 (hr) 2025-11-21
EP3381451B1 (en) 2025-08-20
MX2018002461A (es) 2018-06-07
AU2016314545A1 (en) 2017-11-16
JP2019528297A (ja) 2019-10-10
TWI604859B (zh) 2017-11-11
IL257784A (en) 2018-06-28
CN109069655B (zh) 2024-09-27
PL3381451T3 (pl) 2025-11-12
MX387266B (es) 2025-03-18
US20220362173A1 (en) 2022-11-17
JP7054540B2 (ja) 2022-04-14
DK3381451T3 (da) 2025-10-06
US20180250243A1 (en) 2018-09-06
RU2753507C2 (ru) 2021-08-17
AU2016314545B2 (en) 2019-07-11
AU2019280037A1 (en) 2020-01-16
RU2019108198A3 (zh) 2020-09-21
BR112018003877A2 (pt) 2018-09-25
US12357588B2 (en) 2025-07-15
IL257784B1 (en) 2023-07-01
JP2018531220A (ja) 2018-10-25
AU2016314545C1 (en) 2021-09-23
WO2017037593A2 (zh) 2017-03-09
KR20180039167A (ko) 2018-04-17
CO2018003424A2 (es) 2018-07-10
JP2020128404A (ja) 2020-08-27
EP3381473A4 (en) 2019-10-09
WO2017037593A3 (zh) 2018-08-23
AU2019280037B2 (en) 2021-02-18
JP7095903B2 (ja) 2022-07-05
CN108697668B (zh) 2022-11-04
TW201707686A (zh) 2017-03-01
CN119157850A (zh) 2024-12-20
KR102356390B1 (ko) 2022-02-08
CA2995155A1 (en) 2017-03-09
CN115778928A (zh) 2023-03-14
JP7063804B2 (ja) 2022-05-09
KR20200032768A (ko) 2020-03-26
JP2020143091A (ja) 2020-09-10
JP7063803B2 (ja) 2022-05-09
AU2021202349B2 (en) 2022-12-08
CN108697668A (zh) 2018-10-23
KR20180037058A (ko) 2018-04-10
WO2017037594A2 (zh) 2017-03-09
TWI667044B (zh) 2019-08-01
ES3041835T3 (en) 2025-11-14
AU2016314546B2 (en) 2019-09-12
AU2019246808A1 (en) 2019-10-31
MX2021010359A (es) 2021-10-01
AU2016314546A1 (en) 2018-03-01
MX2018002462A (es) 2018-06-19
BR112018003892A2 (pt) 2018-09-25
FI3381451T3 (fi) 2025-10-10
IL257784B2 (en) 2023-11-01
EP4647070A2 (en) 2025-11-12
AU2016314546C1 (en) 2021-07-22
SG11201801111RA (en) 2018-03-28
US20200163906A1 (en) 2020-05-28
TWI630922B (zh) 2018-08-01
CA2995158A1 (en) 2017-03-09
TW201806584A (zh) 2018-03-01
TW201707685A (zh) 2017-03-01
LT3381451T (lt) 2025-10-10
KR20200049882A (ko) 2020-05-08
KR102240221B1 (ko) 2021-04-14
CN115778928B (zh) 2025-07-25
US11433034B2 (en) 2022-09-06
MX384073B (es) 2025-03-11
PT3381451T (pt) 2025-10-01
KR102107917B1 (ko) 2020-05-08
AU2019246808B2 (en) 2021-01-28
US10610496B2 (en) 2020-04-07
RU2019108198A (ru) 2020-09-21
SMT202500365T1 (it) 2025-11-10
EP3381451A2 (en) 2018-10-03
EP3381473A2 (en) 2018-10-03
EP3381451A4 (en) 2019-10-09
JP2018533545A (ja) 2018-11-15
US20180243211A1 (en) 2018-08-30
CA2995158C (en) 2021-05-11
CN109069655A (zh) 2018-12-21
CA2995155C (en) 2021-05-11

Similar Documents

Publication Publication Date Title
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
WO2014170755A3 (en) Sustained-release formulations of colchicine and methods of using same
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
FI3800177T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
BR112017009510A2 (pt) composições compreendendo ciclosporina
IN2014MU01042A (zh)
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
WO2016040814A3 (en) Disulfide polymers and methods of use
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
MX2022006502A (es) Composiciones farmaceuticas.
BR112017019364A2 (pt) dispersões sólidas
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
PH12016502527A1 (en) Stabilized desmopressin
WO2016126115A3 (en) Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
WO2013168179A3 (en) Controlled release pharmaceutical formulations of antiviral agents
WO2016123482A3 (en) Sustained-release oral dosage forms for low aqueous solubility compounds
WO2013127539A3 (de) Pharmazeutische formulierung enthaltend flupirtin

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2995158

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11201801111R

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 15754429

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2018510970

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/002462

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016314546

Country of ref document: AU

Date of ref document: 20160826

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187008138

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016840922

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018003877

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018003877

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180227

WWG Wipo information: grant in national office

Ref document number: 2016840922

Country of ref document: EP